| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ORIGINAL ARTICLES |
From Roswell Park Cancer Institute, Department of Surgical Oncology, State University of New York at Buffalo, Buffalo, New York.
Correspondence: Address correspondence and reprint requests to: John F. Gibbs, MD, Associate Professor of Surgery, Department of Surgical Oncology, Roswell Park Cancer Institute, Elm and Carlton Sts., Buffalo, NY 14263; Fax: 716-845-3434; E-mail: john.gibbs{at}roswellpark.org
Abstract: Barrett’s esophagus with high-grade dysplasia is a well-known risk factor for the development of esophageal adenocarcinoma, which has become the predominant form of esophageal cancer in the United States. This review addresses four major fundamental issues that shape our treatment decisions regarding high-grade dysplasia within Barrett’s esophagus: (1) the poorly defined natural history of high-grade dysplasia in its progression to adenocarcinoma, (2) the potentially high morbidity and mortality of esophageal resection for high-grade dysplasia, (3) the difficulty in detecting cancer among dysplastic cells during endoscopy, and (4) the controversial role of endoscopic mucosal ablative therapy for high-grade dysplasia. Until there are more accurate surveillance methods, better biochemical or molecular markers in predicting cancerous progression, or more effective minimally invasive methods of treatment, esophagogastrectomy must be considered the standard means of managing patients with Barrett’s esophagus and high-grade dysplasia. Regular rigorous systematic surveillance and endoscopic mucosal ablation are alternative treatment options that are available but should be used only under strict conditions. The decision to proceed in a certain direction is quite complex and challenging and ideally requires the feedback of patients who are properly educated about the controversies surrounding this disease.
Key Words: Barrett’s esophagus • High-grade dysplasia • Esophageal adenocarcinoma • Esophagogastrectomy • Photodynamic therapy
This article has been cited by other articles:
 |
|
 |
|
  F. Yousef, C. Cardwell, M. M. Cantwell, K. Galway, B. T. Johnston, and L. Murray The Incidence of Esophageal Cancer and High-Grade Dysplasia in Barrett's Esophagus: A Systematic Review and Meta-Analysis Am. J. Epidemiol., August 1, 2008; 168(3): 237 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Moraca and D. E. Low Outcomes and Health-Related Quality of Life After Esophagectomy for High-Grade Dysplasia and Intramucosal Cancer Arch Surg, June 1, 2006; 141(6): 545 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. N. Foroulis and J. A. C. Thorpe Photodynamic therapy (PDT) in Barrett's esophagus with dysplasia or early cancer Eur. J. Cardiothorac. Surg., January 1, 2006; 29(1): 30 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. I. Sarela, N. Scott, C. S. Verbeke, J. I. Wyatt, S. P. L. Dexter, H. M. Sue-Ling, and P. J. Guillou Diagnostic Variation and Outcome for High-Grade Gastric Epithelial Dysplasia Arch Surg, July 1, 2005; 140(7): 644 - 649. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Olliver, L. J. Hardie, Y. Gong, S. Dexter, D. Chalmers, K. M. Harris, and C. P. Wild Risk Factors, DNA Damage, and Disease Progression in Barrett's Esophagus Cancer Epidemiol. Biomarkers Prev., March 1, 2005; 14(3): 620 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. T. McManus, A. Olaru, and S. J. Meltzer Biomarkers of Esophageal Adenocarcinoma and Barrett's Esophagus Cancer Res., March 1, 2004; 64(5): 1561 - 1569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Alderson Observer variation in the diagnosis of superficial oesophageal adenocarcinoma: another spanner in the works? Gut, November 1, 2002; 51(5): 620 - 621. [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Peters The Management of Dysplastic Barrett's Esophagus: Where Do We Go From Here? Ann. Surg. Oncol., April 1, 2002; 9(3): 215 - 216. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
